Background

- Over 200 COVID-19 vaccines currently under development, including four in clinical trials in the United States

- ACIP responding to ongoing pandemic and accelerated vaccine development through scheduling of monthly emergency ACIP meetings

- At the July 29th meeting, ACIP reviewed:
  - Overview of COVID-19 vaccine clinical trials
  - COVID-19 vaccine safety considerations
  - Considerations for FDA licensure versus Emergency Use Authorization of COVID-19 vaccines
  - Considerations for vaccine implementation
  - Epidemiology of COVID-19 in essential workers, including healthcare personnel
  - COVID-19 vaccine prioritization: Work Group considerations
  - Evidence to recommendations framework
COVID-19 Vaccine Work Group meets weekly

Topics covered in August:

- Review of COVID-19 epidemiology among at-risk groups, including American Indian/Alaskan Native population and individuals with underlying medical conditions
- Clinical development program for 2 mRNA vaccines, including data from Phase I/II clinical trials and plans for Phase III clinical trials
- Modeling allocation strategies to inform initial COVID-19 vaccine supply
- Initial COVID-19 vaccine distribution scenarios
- COVID-19 vaccine prioritization considerations
Today’s agenda

- mRNA-1273 Clinical Development: Dr. Jacqueline M. Miller (Moderna)
- Pfizer/BioNTech COVID-19 mRNA vaccine Clinical Development: Dr. Nicholas Kitchin (Pfizer/BioNTech)
- Overview of post-marketing safety surveillance: Dr. Tom Shimabukuro (CDC)
- Epidemiology of individuals at increased risk of COVID-19 disease: Dr. Nancy McClung (CDC)
- Modeling allocation strategies for the initial COVID-19 vaccine supply: Dr. Rachel Slayton (CDC)
- Work Group interpretation: Dr. Sara Oliver (CDC)
- Prioritization and Work Group next steps: Dr. Kathleen Dooling (CDC)
Considerations for prioritization of COVID-19 vaccines

Today’s session:
- Focus on individuals at increased risk of COVID-19 disease, including underlying medical conditions and age
- Review of 4 priority groups for consideration of allocation of initial COVID-19 vaccine

September session:
- Focus on epidemiology of risk of COVID-19 by race and ethnicity
- Review of other published prioritization frameworks
- Possible vote on interim prioritization schema for initial COVID-19 vaccine
Work group members

**ACIP members**
- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

**Ex-officio/government members**
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Eric Deussing
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

**CDC Co-leads**
- Kathleen Dooling
- Sara Oliver

**Liaisons**
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

**Liaisons, cont’d**
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Linlu Zhao (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees

**Consultants**
- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)
CDC participants

- Doug Campos-Outcalt
- Mary Chamberland
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Susan Goldstein
- Sam Graitcer
- Lisa Grohskopf
- Rita Helfand
- Terri Hyde

- Tara Jatlaoui
- Cynthia Jorgensen
- Erin Kennedy
- Ram Koppaka
- Jessica MacNeil
- Sarah Mbaeyi
- Nancy McClung
- Rebecca Morgan
- Titilope Oduyebo
- Christina Ottis
- Anita Patel
- Janell Routh
- Stephanie Schrag
- Tom Shimabukuro
- Natalie Thornburg
- Jennifer Verani
- Megan Wallace
- Cindy Weinbaum
- Yon Yu
- Jane Zucker
Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.